Accessibility Menu
 
Arovella Therapeutics Ltd logo

Arovella Therapeutics Ltd

(ASX) ALA

Current Price$0.08
Market Cap$96.70M
Since IPO (2002)-97%
5 Year+100%
1 Year-7%
1 Month+14%

Arovella Therapeutics Ltd Financials at a Glance

Market Cap

$96.70M

Revenue (TTM)

$144.50K

Net Income (TTM)

$14.19M

EPS (TTM)

$-0.01

P/E Ratio

-11.43

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$0.08

Volume

574,902

Open

$0.08

Previous Close

$0.08

Daily Range

$0.08 - $0.08

52-Week Range

$0.07 - $0.13

ALA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arovella Therapeutics Ltd

Industry

Pharmaceuticals

CEO

Michael Baker, PhD, MBA

Headquarters

Osborne Park, WA 6017, AU

ALA Financials

Key Financial Metrics (TTM)

Gross Margin

1%

Operating Margin

5%

Net Income Margin

2%

Return on Equity

-52%

Return on Capital

-84%

Return on Assets

-39%

Earnings Yield

-8.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$96.70M

Shares Outstanding

1.21B

Volume

574.90K

Avg. Volume

873.26K

Financials (TTM)

Gross Profit

$136.00K

Operating Income

$11.20M

EBITDA

$11.10M

Operating Cash Flow

$6.93M

Capital Expenditure

$412.90K

Free Cash Flow

$7.34M

Cash & ST Invst.

$20.88M

Total Debt

$0.00

Arovella Therapeutics Ltd Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$59.15K

+96.0%

Gross Margin

0.00%

N/A

Market Cap

$96.70M

N/A

Market Cap/Employee

$3.58M

N/A

Employees

27

N/A

Net Income

$1.88M

+52.4%

EBITDA

$5.44M

+7.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$19.37M

+306.6%

Accounts Receivable

$126.45K

+13.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-39.15%

N/A

Return on Invested Capital

-83.85%

N/A

Free Cash Flow

$1.76M

+34.4%

Operating Cash Flow

$1.71M

+35.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ILA.AXIsland Pharmaceuticals Limited
$0.37-1.33%
ATH.AXAlterity Therapeutics Limited
$0.01-0.00%
ATX.AXAmplia Therapeutics Limited
$0.15+1.33%
BIO.AXBiome Australia Limited
$0.29-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$12.91+0.04%
SOFISoFi Technologies
$16.10+0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.63+0.10%
MARAMara Holdings
$11.99+0.12%

Questions About ALA

What is the current price of Arovella Therapeutics Ltd?

Arovella Therapeutics Ltd is trading at A$0.08 per share.

What is the 52-week range for Arovella Therapeutics Ltd?

Over the past 52 weeks, Arovella Therapeutics Ltd has traded between A$0.07 and A$0.13.

How much debt does Arovella Therapeutics Ltd have?

As of the most recent reporting period, Arovella Therapeutics Ltd reported total debt of N/A.

How much cash does Arovella Therapeutics Ltd have on hand?

Arovella Therapeutics Ltd reported $20.88M in cash and cash equivalents in its most recent financial results.

What is Arovella Therapeutics Ltd’s dividend yield?

Arovella Therapeutics Ltd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.